HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.

Saved in:
Bibliographic Details
Title: HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.
Authors: Nelde, Annika1,2, Kowalewski, Daniel J.1,3, Backert, Linus1,4, Schuster, Heiko1,3, Werner, Jan-Ole2, Klein, Reinhild2, Kohlbacher, Oliver4,5,6, Kanz, Lothar2, Salih, Helmut R.2,7, Rammensee, Hans-Georg1,8, Stevanović, Stefan1,8, Walz, Juliane S.2 juliane.walz@med.uni-tuebingen.de
Source: OncoImmunology. Apr2018, Vol. 7 Issue 4, p1-12. 12p.
Database: Academic Search Ultimate
Description
ISSN:21624011
DOI:10.1080/2162402X.2017.1316438